Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01970930|
Recruitment Status : Completed
First Posted : October 28, 2013
Last Update Posted : January 19, 2018
|Condition or disease||Intervention/treatment|
|Polycythemia Vera Essential Thrombocythemia||Procedure: Blood specimen|
Specific Aim 1: Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.
Specific Aim 2. Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC.
|Study Type :||Observational|
|Actual Enrollment :||131 participants|
|Official Title:||Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53|
|Study Start Date :||August 2012|
|Primary Completion Date :||June 2, 2016|
|Study Completion Date :||June 2, 2016|
PV or ET
subject who has polycythemia vera or essential thrombocythemia
Procedure: Blood specimen
4 green top tube 40 cc of blood draw
- Stem cell function [ Time Frame: at one time study visit ]Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.
- CD34+ cells assays [ Time Frame: at one time study visit ]Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC. After treatment with RG7112 and IFNα at the various doses, p53, MDM2, MDMX, phosphor-p38, and phosphor-STAT1 levels in MPN CD34+ cells will be measured using monoclonal antibody staining and flow cytometric and immunofluorescence analyses.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01970930
|United States, New York|
|Icahn School of Medicine at Mount Sinai|
|New York, New York, United States, 10029|
|Principal Investigator:||Ronald Hoffman, MD||Icahn School of Medicine at Mount Sinai|